RANIVISIO®
Information for patients and healthcare professionals
The information provided on this page is for general purposes and aims to support the correct and safe use of RANIVISIO (ranibizumab). It is intended to ensure that patients and healthcare professionals are aware of and consider the requirements for the use of RANIVISIO.
Product-related information contained herein is subject to approval by local authorities.
Ongavia®
Information on the safe use of Ongavia® (ranibizumab) in the UK from January 1, 2025, following the agreement of the Windsor Framework.
Reporting of side effects
If you notice any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk
Please ensure that you provide the brand name, and the specific batch-number.
By reporting side effects you can help provide more information on the safety of this medicine.
Alternatively you may report side effects by email to: PV@midas-pharma.com
The data processing is in accordance with the legal requirements. Further information can be found here.